Macropa-NH2 (TFA)

• CAS Number:

  2705054-08-4

• UNSPSC Description:

  Macropa-NH2 TFA is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases[1].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/macropa-nh2-tfa.html

• Purity:

  98.03

• Solubility:

  DMSO : ≥ 130 mg/mL|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(O)C1=NC(CN2CCOCCOCCN(CC3=NC(C(O)=O)=CC=C3)CCOCCOCC2)=CC(N)=C1.O=C(O)C(F)(F)F

• Molecular Weight:

  661.62

• References & Citations:

  [1]Thiele NA, et al. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017;56(46):14712-14717.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported